Legend Biotech Results Presentation Deck
13
Outlook: 2023 and Beyond
NEAR-TERM GOALS
←
←
→
←
Increase manufacturing capacity and efficiency
Ongoing enrollment of CARTITUDE-5
Ongoing enrollment of CARTITUDE-6
Close the transaction with Novartis
Advance pipeline programs
First Ghent facility online by end of this year
Launch lenalidomide refractory 1-3 prior lines indication
based on CARTITUDE-4, if approved by regulatory
authorities. The PDUFA target date is April 5, 2024
This presentation is for investor relations purposes only - Not for product promotional purposes
LONG-TERM GROWTH STRATEGY
→ Focus on unmet medical needs in hematology/oncology
→ Develop therapies with transforming potential
→ Increase accessibility through lower cost and scalable.
manufacturing
→ Build a global powerhouse by leveraging external
collaborations
LEGEND
BIOTECHView entire presentation